Datopotamab deruxtecan met dual primary endpoint of PFS in patients with advanced NSCLC in TROPION-Lung01 Phase III trial July 5, 2023
GAVRETO® (pralsetinib) Supplemental NDA approval by China NMPA for first-line treatment of patients with locally advanced or metastatic RET fusion-positive NSCLC July 5, 2023
505(b)(2) NDA Approval granted from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable June 21, 2023
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919 June 6, 2023
Safety Review Committee Approval to Advance to Ph 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA + Tagrisso in Advanced NSCLC June 6, 2023
KEYTRUDA + Chemo Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC June 6, 2023
New Long-Term Data from the CHRYSALIS Study Show mPFS Not Reached after 33.6 Months of Follow-Up with 1L RYBREVANT + Lazertinib Combo in EGFR-Mutated Advanced NSCLC June 6, 2023
4-Year Outcomes from Ph 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo + Yervoy with 2 Cycles of Chemo for mNSCLC Patients June 6, 2023
Tagrisso achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Ph 3 trial June 6, 2023
FDA Accepts for Priority Review Repotrectinib’s Application for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive NSCLC June 6, 2023
Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1L NSCLC May 31, 2023
Promising New Clinical Data Announced from Triple Combination Therapy in INSIGHT-003 Trial May 31, 2023
FAILED TRIAL: Ph 3 SAPPHIRE study of sitravatinib + (OPDIVO) vs docetaxel in patients with 2/3L advanced NSQ-NSCLC did not meet primary endpoint of OS May 31, 2023
TAGRISSO + chemo demonstrated strong improvement in PFS for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial May 31, 2023
Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer May 31, 2023
Positive CHMP Opinion to Opdivo + Chemo as Neoadjuvant Treatment of Resectable NSCLC at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression May 31, 2023
First Patient Dosed in Ph I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in NSCLC May 18, 2023
The China NMPA Approves TYVYT® + Bevacizumab + Chemotherapy in Patients with EGFR-mutated nsqNSCLC who Progressed after EGFR-TKI Therapy May 18, 2023
Updated Results from ORIENT-31 Study of Sintilimab + Chemo +/- Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated nsqNSCLC announced May 10, 2023
Imfinzi-based treatment before & after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable NSCLC in the AEGEAN Ph 3 trial April 20, 2023
Positive topline data announced from Part A safety lead-in of THIO-101 Ph 2 trial in advanced NSCLC April 20, 2023
Scorpion Therapeutics and Pierre Fabre to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFRm NSCLC April 12, 2023
